BOSTON (

TheStreet

) --Welcome to September's Biotech Stock Live Chat. The floor is yours.

It's been a while since I did one of these chats, so a review of the ground rules: I'm here for the next 90 minutes to answer your biotech-investing questions and, hopefully, spark some interactive debate on the hot topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.

If you're at a loss for topics, I have some suggestions that riff off my

2012 Biotech Stock Fall Preview

.

With

Vivus

(VVUS) - Get Report

announcing the commercial launch of Qsymia on Monday, the weight-loss market share war with

Arena Pharmaceuticals

(ARNA) - Get Report

ratchets up a notch.

Amarin

(AMRN) - Get Report

: NCE status, when? Vascepa launch? Takeout or partnership?

Let's debate

Sunesis Pharmaceuticals

(SNSS) - Get Report

vs

Cyclacel Pharmaceuticals

(CYCC) - Get Report

. Which company has the better drug for acute myeloid leukemia?

Can

Acadia Pharmaceuticals

(ACAD) - Get Report

and its Parkinson's disease drug pimavanserin succeed in the current phase III trial?

Can

Exelixis

(EXEL) - Get Report

or

Ariad Pharmaceuticals

(ARIA)

garner early FDA approval for their respective cancer drugs?

Let's look ahead to see what's in store for hepatitis C drug stocks like

Gilead Sciences

(GILD) - Get Report

,

Idenix Pharmaceuticals

(IDIX)

and

Vertex Pharmaceuticals

(VRTX) - Get Report

.

Will

Peregrine Pharmaceuticals

(PPHM)

sign a partner before starting the bavituximab phase III lung cancer study at year's end, as promised?

Sarepta Therapeutics

(SRPT) - Get Report

!

Let's talk about these stocks today, or any other biotech -investing subject that piques your interest. Please join me live.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.